Melanotan I: Dosage, Protocol, and Research Guide
Alpha-MSH analog for skin pigmentation without libido effects
Mechanism
Activates melanocortin-1 receptors to stimulate melanogenesis without significant MC4R activation
Protocol at a glance
| Starting dose | 0.5mg |
|---|---|
| Maintenance dose | 1mg |
| Maximum dose | 1mg |
| Frequency | Daily until tan, then 1-2x weekly |
| Typical duration | 4-8 weeks loading |
| Route | Subcutaneous |
| Injection site | Abdomen |
| Timing | Evening |
Side effects
- Nausea
- Facial flushing
- Fatigue
- Increased freckling
Contraindications
- Melanoma history
- Pregnancy
Protocol notes
- Less libido effects than MT-II
- FDA approved as Scenesse
- Provides photoprotection
- Loading phase required
- Monitor moles/freckles
Frequently asked questions
How does Melanotan I differ from Melanotan II?
Melanotan I is specifically engineered to activate melanocortin-1 receptors while minimizing activation of melanocortin-4 receptors. This selective targeting produces significant tanning effects without the pronounced libido effects associated with Melanotan II. For users prioritizing skin pigmentation effects without sexual function changes, Melanotan I represents the more targeted option. Both peptides operate through melanin stimulation, but Melanotan I's receptor selectivity creates a more focused effect profile.
What is the standard Melanotan I dosing protocol?
Melanotan I follows a two-phase protocol. Start with 0.5mg daily, escalating to 1mg daily during the loading phase, which continues for 4 to 8 weeks until desired tan is achieved. Once pigmentation goals are reached, transition to maintenance dosing of 1mg, 1-2 times weekly. The maximum dose is 1mg. Administration is via subcutaneous injection into the abdomen, with evening as the preferred timing. This phased approach allows melanin accumulation while minimizing total long-term peptide exposure.
What side effects should I expect from Melanotan I?
Common side effects include nausea, facial flushing, fatigue, and increased freckling. These effects are typically transient and manageable, particularly when dosing begins conservatively at 0.5mg and escalates gradually. Most users report that side effects diminish as the body acclimates during the loading phase. Individual tolerance varies, so monitoring your response during the initial weeks before advancing to higher doses or full maintenance is important.
How long does Melanotan I take to produce visible results?
Visible tanning typically develops progressively throughout the 4 to 8-week loading phase. Because Melanotan I stimulates the body's natural melanin production through melanocortin-1 receptor activation, results emerge gradually as melanocytes respond to the peptide's signaling. Most users report noticeable tan development within 2 to 3 weeks, with deepening occurring throughout the loading period. Once the loading phase completes, maintenance dosing at 1-2 times weekly sustains the achieved pigmentation.
Who should not use Melanotan I?
Melanotan I has two absolute contraindications: a personal history of melanoma and pregnancy. Because Melanotan I stimulates melanin production through melanocortin-1 receptor activation, individuals with prior melanoma face theoretical risk from upregulation of melanogenesis. Reproductive safety data is unavailable, making pregnancy a clear exclusion criterion. Additionally, close monitoring of existing moles and freckles is advised during use, as the peptide's melanin-stimulating effect may influence pigmented lesions.
Does Melanotan I provide sun protection?
Research has examined Melanotan I and its FDA-approved pharmaceutical analog (Scenesse/afamelanotide) for photoprotective effects. The peptide's mechanism—stimulating melanin production—provides the body with increased endogenous pigmentation, which functions as natural UV defense. This photoprotective benefit distinguishes Melanotan I from cosmetic-only tanning approaches, as the melanin produced serves both aesthetic and protective functions. However, this property also reinforces the importance of monitoring existing moles and freckles, as melanin upregulation affects the entire pigmentation system.
How does the Melanotan I loading and maintenance cycle work?
Melanotan I is designed around a two-phase cycle optimized for efficiency and tolerability. The loading phase spans 4 to 8 weeks of daily dosing, starting at 0.5mg and escalating to 1mg, during which melanin accumulates in the skin. Once desired pigmentation is visibly achieved, users transition to the maintenance phase, reducing dosing frequency to 1-2 times weekly while maintaining the 1mg per-dose amount. This cycling approach enables sustained results with significantly lower ongoing peptide exposure compared to continuous daily use.
Can Melanotan I be combined with other peptides or compounds?
Research on Melanotan I stacking with other peptides remains limited. Any protocol involving Melanotan I combined with additional compounds should be carefully evaluated in consultation with a healthcare provider, particularly given the peptide's specific mechanism (melanocortin-1 receptor activation) and absolute contraindications around melanoma history and pregnancy. The safety profile of combination use falls outside the scope of available clinical and research data for Melanotan I.
More Cosmetic & Aesthetic peptides · All peptide guides · Free dose calculator
Educational reference only — not medical advice. Work with a qualified clinician.